curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Company profile
Ticker
CRIS
Exchange
Website
CEO
James Dentzer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Curis Securities Corporation • Curis Royalty LLC ...
IRS number
43505116
CRIS stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
15 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
S-8
Registration of securities for employees
8 Feb 24
S-3
Shelf registration
8 Feb 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Curis Provides Fourth Quarter 2023 Business Update
8 Feb 24
8-K
Corporate Presentation January 2024
11 Jan 24
Transcripts
CRIS
Earnings call transcript
2023 Q4
8 Feb 24
CRIS
Earnings call transcript
2023 Q3
2 Nov 23
CRIS
Earnings call transcript
2023 Q2
3 Aug 23
CRIS
Earnings call transcript
2023 Q1
4 May 23
CRIS
Earnings call transcript
2022 Q4
13 Mar 23
CRIS
Earnings call transcript
2022 Q3
10 Nov 22
CRIS
Earnings call transcript
2022 Q2
5 Aug 22
CRIS
Earnings call transcript
2022 Q1
5 May 22
CRIS
Earnings call transcript
2021 Q4
25 Feb 22
CRIS
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
SC 13G
KINGDON CAPITAL MANAGEMENT, L.L.C.
15 Apr 24
SC 13G/A
MAVERICK CAPITAL LTD
14 Feb 24
SC 13G
M28 Capital Management LP
12 Feb 24
4
Jonathan B. Zung
3 May 23
3
Jonathan B. Zung
3 May 23
SC 13G/A
MAVERICK CAPITAL LTD
14 Feb 23
4
KENNETH I KAITIN
24 Jan 23
4
John Hohneker
24 Jan 23
4
Marc Rubin
24 Jan 23
4
MARTYN D GREENACRE
24 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm |
Cash burn (monthly) | (no burn) | 456.17 k | 4.12 mm | 3.86 mm | 2.73 mm | 3.38 mm |
Cash used (since last report) | n/a | 3.05 mm | 27.57 mm | 25.83 mm | 18.24 mm | 22.58 mm |
Cash remaining | n/a | 21.96 mm | -2.56 mm | -821.86 k | 6.77 mm | 2.43 mm |
Runway (months of cash) | n/a | 48.1 | -0.6 | -0.2 | 2.5 | 0.7 |
Institutional ownership, Q3 2023
46.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 3 |
Closed positions | 27 |
Increased positions | 1 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 12.77 bn |
Total shares | 2.75 mm |
Total puts | 0.00 |
Total calls | 215.70 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 626.95 k | $5.14 mm |
Maverick Capital | 582.27 k | $3.84 bn |
M28 Capital Management | 421.95 k | $2.78 bn |
Kingdon Capital Management, L.L.C. | 309.15 k | $2.04 bn |
Vanguard | 179.87 k | $1.19 bn |
Artal | 105.00 k | $692.00 k |
C Citigroup | 91.87 k | $605.43 mm |
Renaissance Technologies | 85.56 k | $564.00 k |
Alyeska Investment | 78.14 k | $514.91 mm |
BLK Blackrock | 53.50 k | $352.53 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 23 | Jonathan B. Zung | Employee stock option Common Stock | Grant | Acquire A | No | No | 0.83 | 500,000 | 415.00 k | 500,000 |
23 Jan 23 | Anne Elizabeth Borgman | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
23 Jan 23 | Marc Rubin | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
23 Jan 23 | Martyn D Greenacre | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
News
Top 3 Health Care Stocks That May Collapse In Q2
12 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
9 Feb 24
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26
9 Feb 24
Curis Q4 EPS $(2.03) Beats $(2.11) Estimate, Sales $2.70M Miss $3.02M Estimate
8 Feb 24
Press releases
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 Apr 24
Curis to Present at Upcoming Healthcare Conferences in April
4 Apr 24
Curis to Present at Upcoming Healthcare Conferences in April
4 Apr 24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
2 Apr 24
Curis Provides Fourth Quarter 2023 Business Update
8 Feb 24